Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/+WAPCre mouse model

Table 1 Results overview of p53 ^R270H/+ WAPCre model subcutaneously injected with growth factors

Tested variable	Insulin	Glargine	X10	IGF1	Vehicle
Number of mice analyzed	40	40	40	40	38
Mortality	6/40 (15%)	3/40 (8%)	5/40 (13%)	4/40 (10%)	1/38 (3%)
Mean weight of mice (grams)^a	30 ± 0.5	30 ± 0.5	32 ± 0.6	34 ± 0.7	29 ± 0.4
P-value^b	0.1996	0.1567	0.0002	<0.0001	NA
Tumor-bearing mice	34/34 (100%)	37/37 (100%)	35/35 (100%)	36/36 (100%)	37/37 (100%)
Mean tumor latency-time (weeks)^c	44.9	38.0	37.9	36.0	42.6
P-value^d	0.1463	0.1448	0.0707	0.0549	NA
Mammary gland tumor	29/34 (85%)	31/37 (84%)	31/35 (89%)	28/36 (78%)	29/37 (78%)
Carcinocarcoma	24/29 (83%)	25/31 (81%)	26/31 (84%)	25/28 (89%)	23/29 (79%)
EMT status (% epithelial)	20.8 ± 4.89	27.5 ± 4.83	31.2 ± 4.01	18.8 ± 4.71	15.71 ± 3.80
P-value^b	0.2170	0.0672	0.0086	0.6251	NA
Carcinoma	5/29 (17%)	5/31 (16%)	5/31 (16%)	3/28 (11%)	6/29 (21%)
Adenoma	0/29	1/31 (3%)	0/31	0/28	0/29
Mean MG tumor latency-time (weeks)^c	45.0	41.9	37.9	38.4	44.9
P-value^d	0.8329	0.0688	0.0044	0.0207	NA
Mean MG tumor doubling time (days)	1.75 ± 0.11	1.87 ± 0.21	1.83 ± 0.19	1.53 ± 0.12	1.470 ± 0.14
P-value^b	0.1375	0.1305	0.1632	0.7594	NA
Mice with multiple MG tumors	10/34 (29%)	16/37 (43%)	18/35 (51%)	16/36 (44%)	13/37 (35%)
Average number of MG tumors	1.50 ± 0.16	2.00 ± 0.24	1.82 ± 0.16	2.07 ± 0.23	1.64 ± 0.15
P-value^b	0.5289	0.2371	0.4337	0.1346	NA

^aMean weight depicted as average weight of mice from start of injections (mice are ± 8 wks) until mice are sacrificed; ^bmean latency time is depicted as number of weeks after start of the subcutaneous injections; ^c P-values determined by comparing the Kaplan-Meijer curves of compounds with vehicle; ^d P-values determined by comparing compounds with vehicle, unpaired t-test. EMT, epithelial to mesenchymal transition; MG, mammary gland.

ISSN: 1465-542X